That is in the same vicinity as the results seen with Boehringer Ingelheim's rival SGLT2 inhibitor Jardiance (empagliflozin) in the EMPEROR-Preserved in July 2021 in heart failure preserved ...

Researchers analyzed concentrations of microplastics in 91 brain tissue samples collected during autopsies in 2016 and 2024. The samples were from the frontal cortex, the brain region above and behind ...

Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised or recently discharged with heart failure, regardless of their LVEF status.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...